Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease
Launched by SHIRE · Sep 7, 2005
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients receiving haemodialysis for ESRD
- • Patients must have received haemodialysis for chronic renal failure three times per week for at least the previous 2 months
- Exclusion Criteria:
- • Pregnant or lactating women
- • Patients with clinically significant uncontrolled concurrent illness, a life-threatening malignancy or current multiple myeloma
- • Patients who are HIV+
- • Patients with any significant bowel obstruction, active inflammatory bowel disease, GI motility disorders, or a history of major GI surgery within the last 6 months
About Shire
Shire, a global biotechnology company, specializes in developing innovative therapies for rare diseases and complex conditions. With a strong commitment to improving the lives of patients, Shire focuses on areas such as hematology, immunology, neuroscience, and genetic disorders. The company is dedicated to advancing clinical research and delivering breakthrough treatments that address unmet medical needs. Through collaboration and a patient-centric approach, Shire strives to enhance health outcomes and empower individuals affected by challenging health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Study Director
Study Director
Takeda
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials